BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, Swoboda KJ, Kiernan MC. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 2017;81:355-68. [PMID: 28026041 DOI: 10.1002/ana.24864] [Cited by in Crossref: 122] [Cited by in F6Publishing: 128] [Article Influence: 24.4] [Reference Citation Analysis]
Number Citing Articles
1 Gomez Limia C, Baird M, Schwartz M, Saxena S, Meyer K, Wein N. Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders. JPM 2022;12:1979. [DOI: 10.3390/jpm12121979] [Reference Citation Analysis]
2 Kotulska K, Jozwiak S, Jedrzejowska M, Gos M, Ogrodnik M, Wysocki J, Czajka H, Kuchar E. Newborn screening and gene therapy in SMA: Challenges related to vaccinations. Front Neurol 2022;13. [DOI: 10.3389/fneur.2022.890860] [Reference Citation Analysis]
3 Noguchi Y, Bo R, Nishio H, Matsumoto H, Matsui K, Yano Y, Sugawara M, Ueda G, Wijaya YOS, Niba ETE, Shinohara M, Bouike Y, Takeuchi A, Okamoto K, Saito T, Shimomura H, Lee T, Takeshima Y, Iijima K, Nozu K, Awano H. PCR-Based Screening of Spinal Muscular Atrophy for Newborn Infants in Hyogo Prefecture, Japan. Genes 2022;13:2110. [DOI: 10.3390/genes13112110] [Reference Citation Analysis]
4 Iwayama H, Kawahara K, Takagi M, Numoto S, Azuma Y, Kurahashi H, Yasue Y, Kawajiri H, Yanase A, Ito T, Kimura S, Kumagai T, Okumura A. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2. Brain and Development 2022. [DOI: 10.1016/j.braindev.2022.10.006] [Reference Citation Analysis]
5 Meza ME, Almaraz-espinoza A. Clinical Experience with Disease-Modifying Therapies in Adolescent and Adult Patients with Spinal Muscular Atrophy Type 2 and Type 3 in Mexico: Case Report. SN Compr Clin Med 2022;4:208. [DOI: 10.1007/s42399-022-01217-x] [Reference Citation Analysis]
6 Li Y, Huang B, Xue Z, Gao Y, Zhuo Z. Nucleic acid therapy in pediatric cancer. Pharmacol Res 2022;184:106441. [PMID: 36096420 DOI: 10.1016/j.phrs.2022.106441] [Reference Citation Analysis]
7 Ramos-platt L, Elman L, Shieh PB. Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy. IJGM 2022;Volume 15:7341-7353. [DOI: 10.2147/ijgm.s369021] [Reference Citation Analysis]
8 Wang T, Scuffham P, Byrnes J, Downes M. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia. J Neurol 2022. [PMID: 35980467 DOI: 10.1007/s00415-022-11319-0] [Reference Citation Analysis]
9 Shih STF, Keller E, Wiley V, Farrar MA, Wong M, Chambers GM. Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency. IJNS 2022;8:45. [DOI: 10.3390/ijns8030045] [Reference Citation Analysis]
10 Barnes L, Gutierrez R, Mccrady A, Tolman S, Boukhechba M, Blemker S, Scharf R, Masterson C. Upper EXTremity Examination for Neuromuscular Diseases (U-EXTEND): Protocol for multi-modal feasibility study (Preprint). JMIR Research Protocols. [DOI: 10.2196/40856] [Reference Citation Analysis]
11 Barnes L, Gutierrez R, Mccrady A, Tolman S, Boukhechba M, Blemker S, Scharf R, Masterson C. Upper EXTremity Examination for Neuromuscular Diseases (U-EXTEND): A protocol for a feasibility study to explore the use of wearable sensors and ultrasound techniques to develop novel measures for muscle function (Preprint).. [DOI: 10.2196/preprints.40856] [Reference Citation Analysis]
12 Hjartarson HT, Nathorst-böös K, Sejersen T. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence. DDDT 2022;Volume 16:1865-1883. [DOI: 10.2147/dddt.s214174] [Reference Citation Analysis]
13 Zhang L, Abendroth F, Vázquez O. A Chemical Biology Perspective to Therapeutic Regulation of RNA Splicing in Spinal Muscular Atrophy (SMA). ACS Chem Biol 2022. [PMID: 35639849 DOI: 10.1021/acschembio.2c00161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chamakioti M, Karantzelis N, Taraviras S. Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies. Int J Mol Sci 2022;23:4824. [PMID: 35563214 DOI: 10.3390/ijms23094824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yamadera M, Saito T, Shinohara M, Nishio H, Murayama S, Fujimura H. Spinal muscular atrophy type 2 patient who survived 61 years: an autopsy case report. Neuropathology 2022. [PMID: 35144320 DOI: 10.1111/neup.12784] [Reference Citation Analysis]
16 MacCannell D, Berger Z, Kirschner J, Mercuri E, Farrar MA, Iannaccone ST, Kuntz NL, Finkel RS, Valente M, Muntoni F. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model. CNS Drugs 2022. [PMID: 35080757 DOI: 10.1007/s40263-022-00899-0] [Reference Citation Analysis]
17 Gutic M, Milidrag A, Cikotic AG, Danilovic M, Safiye T, Bulatovic I, Milosavljevic MN, Jankovic S. Rare Neurological Diseases: an Overreview of Pathophysiology, Epidemiology, Clinical Features and Pharmacoeconomic Considerations in the Treating. Serbian Journal of Experimental and Clinical Research 2021;0. [DOI: 10.2478/sjecr-2021-0049] [Reference Citation Analysis]
18 Deng S, Lee BH, Ciafaloni E. Parent Perceptions in Choosing Treatment for Infants With Spinal Muscular Atrophy Diagnosed Through Newborn Screening. J Child Neurol 2022;37:43-9. [PMID: 34753336 DOI: 10.1177/08830738211040292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Edinoff AN, Nguyen LH, Odisho AS, Maxey BS, Pruitt JW, Girma B, Cornett EM, Kaye AM, Kaye AD. The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy. Orthop Rev (Pavia) 2021;13:24934. [PMID: 34745470 DOI: 10.52965/001c.24934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
20 Mercuri E. Spinal muscular atrophy: from rags to riches. Neuromuscul Disord 2021;31:998-1003. [PMID: 34736637 DOI: 10.1016/j.nmd.2021.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Kotulska K, Fattal-Valevski A, Haberlova J. Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy. Front Neurol 2021;12:726468. [PMID: 34721262 DOI: 10.3389/fneur.2021.726468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Schloss N, Wirth B, Kruse T, Lehmann HC, Wunderlich G. Diagnostik und Therapie der spinalen Muskelatrophie (SMA) bei Erwachsenen. DGNeurologie 2021;4:501-515. [DOI: 10.1007/s42451-021-00386-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health 2021:S2352-4642(21)00287-X. [PMID: 34756190 DOI: 10.1016/S2352-4642(21)00287-X] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
24 Thomsen G, Burghes AHM, Hsieh C, Do J, Chu BTT, Perry S, Barkho B, Kaufmann P, Sproule DM, Feltner DE, Chung WK, McGovern VL, Hevner RF, Conces M, Pierson CR, Scoto M, Muntoni F, Mendell JR, Foust KD. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat Med 2021;27:1701-11. [PMID: 34608334 DOI: 10.1038/s41591-021-01483-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
25 Chilcott EM, Muiruri EW, Hirst TC, Yáñez-Muñoz RJ. Systematic review and meta-analysis determining the benefits of in vivo genetic therapy in spinal muscular atrophy rodent models. Gene Ther 2021. [PMID: 34611322 DOI: 10.1038/s41434-021-00292-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Halanski MA, Hanna R, Bernatz J, Twedt M, Sund S, Patterson K, Noonan KJ, Schultz M, Schroth MK, Sharafinski M, Hasley BP. Sagittal Plane Deformities in Children with SMA2 following Posterior Spinal Instrumentation. Children (Basel) 2021;8:703. [PMID: 34438594 DOI: 10.3390/children8080703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Slayter J, Hodgkinson V, Lounsberry J, Brais B, Chapman K, Genge A, Izenberg A, Johnston W, Lochmüller H, O'Ferrall E, Pfeffer G, Plamondon S, Rodrigue X, Schellenberg K, Shoesmith C, Stables C, Taillon M, Warman-Chardon J, Korngut L, O'Connell C. A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method. J Neuromuscul Dis 2021;8:579-88. [PMID: 33867362 DOI: 10.3233/JND-200617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Shih ST, Farrar MA, Wiley V, Chambers G. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry 2021:jnnp-2021-326344. [PMID: 34321343 DOI: 10.1136/jnnp-2021-326344] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
29 Baker MW, Mochal ST, Dawe SJ, Wiberley-Bradford AE, Cogley MF, Zeitler BR, Piro ZD, Harmelink MM, Kwon JM. Newborn screening for spinal muscular atrophy: The Wisconsin first year experience. Neuromuscul Disord 2021:S0960-8966(21)00585-X. [PMID: 35120759 DOI: 10.1016/j.nmd.2021.07.398] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Sansone VA, Walter MC, Attarian S, Delstanche S, Mercuri E, Lochmüller H, Neuwirth C, Vazquez-Costa JF, Kleinschnitz C, Hagenacker T. Measuring Outcomes in Adults with Spinal Muscular Atrophy - Challenges and Future Directions - Meeting Report. J Neuromuscul Dis 2020;7:523-34. [PMID: 32538864 DOI: 10.3233/JND-200534] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 25.0] [Reference Citation Analysis]
31 Ali HG, Ibrahim K, Elsaid MF, Mohamed RB, Abeidah MIA, Al Rawwas AO, Elshafey K, Almulla H, El-Akouri K, Almulla M, Othman A, Musa S, Al-Mesaifri F, Ali R, Shahbeck N, Al-Mureikhi M, Alsulaiman R, Alkaabi S, Ben-Omran T. Gene therapy for spinal muscular atrophy: the Qatari experience. Gene Ther 2021. [PMID: 34276047 DOI: 10.1038/s41434-021-00273-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
32 Naveed A, Calderon H. Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy. J Pediatr Pharmacol Ther 2021;26:437-44. [PMID: 34239394 DOI: 10.5863/1551-6776-26.5.437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Bashiri FA, Temsah MH, Hundallah K, Alsohime F, AlRuthia Y. 2020 Update to Spinal Muscular Atrophy Management in Saudi Arabia. Front Pediatr 2021;9:684134. [PMID: 34136444 DOI: 10.3389/fped.2021.684134] [Reference Citation Analysis]
34 Gaudet G, Raison M, Achiche S. Current Trends and Challenges in Pediatric Access to Sensorless and Sensor-Based Upper Limb Exoskeletons. Sensors (Basel) 2021;21:3561. [PMID: 34065366 DOI: 10.3390/s21103561] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Yung NK, Maassel NL, Ullrich SJ, Ricciardi AS, Stitelman DH. A narrative review of in utero gene therapy: advances, challenges, and future considerations. Transl Pediatr 2021;10:1486-96. [PMID: 34189107 DOI: 10.21037/tp-20-89] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Stępień A, Osiak T, Rekowski W, Wit A. Neck and Trunk Muscle Strength in Children With Spinal Muscular Atrophy Is Lower Than in Healthy Controls and Depends on Disease Type. Front Neurol 2021;12:628414. [PMID: 33995241 DOI: 10.3389/fneur.2021.628414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Pathan A, Bairagi V. Onasemnogene Abeparvovec-xioi: World’s most expensive and approved therapy for spinal muscular atrophy. NeuroPharmac J 2021. [DOI: 10.37881/1.612] [Reference Citation Analysis]
38 Huff HV, Huff KR. Hypotonia. Berkowitz’s Pediatrics 2021. [DOI: 10.1542/9781610023733-128] [Reference Citation Analysis]
39 Lusakowska A, Jedrzejowska M, Kaminska A, Janiszewska K, Grochowski P, Zimowski J, Sierdzinski J, Kostera-Pruszczyk A. Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy. Orphanet J Rare Dis 2021;16:150. [PMID: 33761963 DOI: 10.1186/s13023-021-01771-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
40 Gusset N, Stalens C, Stumpe E, Klouvi L, Mejat A, Ouillade MC, de Lemus M. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Neuromuscul Disord 2021;31:419-30. [PMID: 33752935 DOI: 10.1016/j.nmd.2021.01.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
41 Edel L, Grime C, Robinson V, Manzur A, Abel F, Munot P, Ridout D, Scoto M, Muntoni F, Chan E. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs. Neuromuscul Disord 2021;31:300-9. [PMID: 33752934 DOI: 10.1016/j.nmd.2021.01.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Kim AR, Lee JM, Min YS, Lee H, Kim D, Hwang SK, Kwon S, Lee YJ. Clinical Experience of Nusinersen in a Broad Spectrum of Spinal Muscular Atrophy: A Retrospective Study. Ann Indian Acad Neurol 2020;23:796-801. [PMID: 33688130 DOI: 10.4103/aian.AIAN_524_20] [Reference Citation Analysis]
43 Osmanovic A, Ranxha G, Kumpe M, Wurster CD, Stolte B, Cordts I, Günther R, Freigang M, Müschen LH, Binz C, Hermann A, Deschauer M, Lingor P, Ludolph AC, Hagenacker T, Schreiber-Katz O, Petri S. Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy. Ther Adv Neurol Disord 2021;14:1756286421998902. [PMID: 33747131 DOI: 10.1177/1756286421998902] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
44 Kwatra M, Ahmed S, Ranjan Panda S, Ganga Modi Naidu V, Gupta N. Molecular Mechanisms, Therapeutic Targets and Pharmacological Interventions: An Update. Background and Management of Muscular Atrophy 2021. [DOI: 10.5772/intechopen.95996] [Reference Citation Analysis]
45 Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol 2021;37:100878. [PMID: 33892848 DOI: 10.1016/j.spen.2021.100878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
46 Roessler HI, Knoers NVAM, van Haelst MM, van Haaften G. Drug Repurposing for Rare Diseases. Trends Pharmacol Sci 2021;42:255-67. [PMID: 33563480 DOI: 10.1016/j.tips.2021.01.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 38.0] [Reference Citation Analysis]
47 Vissers MFJM, Heuberger JAAC, Groeneveld GJ. Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders. Int J Mol Sci 2021;22:1615. [PMID: 33562713 DOI: 10.3390/ijms22041615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Chen TH. Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy. Ther Adv Neurol Disord 2020;13:1756286420979954. [PMID: 33488772 DOI: 10.1177/1756286420979954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
49 Yao M, Ma Y, Qian R, Xia Y, Yuan C, Bai G, Mao S. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study. Orphanet J Rare Dis 2021;16:7. [PMID: 33407670 DOI: 10.1186/s13023-020-01638-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
50 Kerpel-Fronius S, Baroutsou V, Becker S, Carlesi R, Collia L, Franke-Bray B, Kleist P, Kurihara C, Laranjeira LF, Matsuyama K, Naseem S, Schenk J, Silva H. Development and Use of Gene Therapy Orphan Drugs-Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society. Front Med (Lausanne) 2020;7:608249. [PMID: 33425952 DOI: 10.3389/fmed.2020.608249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Li YJ, Chen TH, Wu YZ, Tseng YH. Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy. Nutrients 2020;12:E3842. [PMID: 33339220 DOI: 10.3390/nu12123842] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
52 Jędrzejowska M. Advances in Newborn Screening and Presymptomatic Diagnosis of Spinal Muscular Atrophy. Degener Neurol Neuromuscul Dis 2020;10:39-47. [PMID: 33364872 DOI: 10.2147/DNND.S246907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
53 Gonski K, Fitzgerald DA. Respiratory outcomes post nusinersen in spinal muscular atrophy type 1. Pediatr Pulmonol 2021;56:807-8. [PMID: 33316146 DOI: 10.1002/ppul.25209] [Reference Citation Analysis]
54 Ropars J, Peudenier S, Genot A, Barnerias C, Espil C. Multidisciplinary approach and psychosocial management of spinal muscular atrophy (SMA). Archives de Pédiatrie 2020;27:7S45-9. [DOI: 10.1016/s0929-693x(20)30277-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Sah JP, Abrams AW, Chari G, Linden C, Anziska Y. Hydrocephalus in Spinal Muscular Atrophy: A Case Report and Review of the Literature. Journal of Pediatric Neurology 2021;19:352-4. [DOI: 10.1055/s-0040-1721131] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Machacek ME, Gogakos T, Fletcher MC, Lunderville KA, Swoboda KJ, Sohani AR. Unusual inclusions in cerebrospinal fluid macrophages of spinal muscular atrophy patients treated with nusinersen. Int J Lab Hematol 2021;43:e104-6. [PMID: 33201586 DOI: 10.1111/ijlh.13392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Müller-Felber W, Vill K, Schwartz O, Gläser D, Nennstiel U, Wirth B, Burggraf S, Röschinger W, Becker M, Durner J, Eggermann K, Müller C, Hannibal I, Olgemöller B, Schara U, Blaschek A, Kölbel H. Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden? J Neuromuscul Dis 2020;7:109-17. [PMID: 32144995 DOI: 10.3233/JND-200475] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
58 Iftikhar M, Frey J, Shohan MJ, Malek S, Mousa SA. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. Pharmacol Ther 2021;220:107719. [PMID: 33130193 DOI: 10.1016/j.pharmthera.2020.107719] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
59 Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy - insights and challenges in the treatment era. Nat Rev Neurol 2020;16:706-15. [PMID: 33057172 DOI: 10.1038/s41582-020-00413-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
60 Schorling DC, Pechmann A, Kirschner J. Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. J Neuromuscul Dis 2020;7:1-13. [PMID: 31707373 DOI: 10.3233/JND-190424] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 30.5] [Reference Citation Analysis]
61 Farrar MA, Kiernan MC. Treating adults with spinal muscular atrophy with nusinersen. J Neurol Neurosurg Psychiatry 2020;91:1139. [PMID: 32917825 DOI: 10.1136/jnnp-2020-324036] [Reference Citation Analysis]
62 D'Silva A, Farrar MA. Personalized medicine for children with spinal muscular atrophy: Toward the holy grail. Muscle Nerve 2020;62:425-6. [PMID: 32696479 DOI: 10.1002/mus.27030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Alghamdi F, Alshaikh N, Bamaga AK, Bashiri FA, Hundullah K, Alshehri A, Al-Muhaizea MA, Al-Saman A. A consensus statement on spinal muscular atrophy management in Saudi Arabia in the context of COVID-19. Neurosciences (Riyadh) 2020;25:230-7. [PMID: 32683408 DOI: 10.17712/nsj.2020.3.20200083] [Reference Citation Analysis]
64 Bernatz JT, Anderson PA, Halanski MA. Cervical Kyphosis in Spinal Muscular Atrophy: A Case Report. JBJS Case Connect 2020;10:e1900341. [PMID: 32649147 DOI: 10.2106/JBJS.CC.19.00341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Connock M, Andronis L, Auguste P, Dussart C, Armoiry X. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert Opin Biol Ther 2020;20:823-7. [PMID: 32434404 DOI: 10.1080/14712598.2020.1772747] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
66 Matesanz SE, Curry C, Gross B, Rubin AI, Linn R, Yum SW, Kichula EA. Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec. J Child Neurol 2020;35:717-23. [PMID: 32515646 DOI: 10.1177/0883073820928784] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
67 Chambers GM, Settumba SN, Carey KA, Cairns A, Menezes MP, Ryan M, Farrar MA. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology 2020;95:e1-e10. [DOI: 10.1212/wnl.0000000000009715] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
68 Greener M. Making sense of antisense oligonucleotide therapy. Prescriber 2020;31:15-18. [DOI: 10.1002/psb.1848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Raimer AC, Singh SS, Edula MR, Paris-Davila T, Vandadi V, Spring AM, Matera AG. Temperature-sensitive spinal muscular atrophy-causing point mutations lead to SMN instability, locomotor defects and premature lethality in Drosophila. Dis Model Mech 2020;13:dmm043307. [PMID: 32501283 DOI: 10.1242/dmm.043307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
70 Peterson I, Cruz R, Sarr F, Stanley AM, Jarecki J. The SMA Clinical Trial Readiness Program: creation and evaluation of a program to enhance SMA trial readiness in the United States. Orphanet J Rare Dis 2020;15:118. [PMID: 32443972 DOI: 10.1186/s13023-020-01387-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
71 Chen TH. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? Int J Mol Sci. 2020;21. [PMID: 32392694 DOI: 10.3390/ijms21093297] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
72 Ross T, Buliung R, Murphy A, Howard A. A visual ethnographic pilot study of school travel for families living with childhood disability. Children's Geographies 2020;18:283-97. [DOI: 10.1080/14733285.2019.1635991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Ross LF, Kwon JM. Spinal Muscular Atrophy: Past, Present, and Future. Neoreviews 2019;20:e437-51. [PMID: 31371553 DOI: 10.1542/neo.20-8-e437] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
74 Zhu S, Rooney S, Michlewski G. RNA-Targeted Therapies and High-Throughput Screening Methods. Int J Mol Sci 2020;21:E2996. [PMID: 32340368 DOI: 10.3390/ijms21082996] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
75 Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E, Stahl K, Pechmann A, Lochmüller H, Kirschner J, Schoser B. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. J Neuromuscul Dis 2019;6:453-65. [PMID: 31594243 DOI: 10.3233/JND-190416] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 46.0] [Reference Citation Analysis]
76 Farrar MA, Carey KA, Paguinto S, Kasparian NA, De Abreu Lourenço R. “The Whole Game is Changing and You’ve Got Hope”: Australian Perspectives on Treatment Decision Making in Spinal Muscular Atrophy. Patient 2020;13:389-400. [DOI: 10.1007/s40271-020-00415-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
77 Williams L. Spinal Muscular Atrophy in the Age of Gene Therapy. AACN Advanced Critical Care 2020;31:86-91. [DOI: 10.4037/aacnacc2020436] [Reference Citation Analysis]
78 Wan HWY, Carey KA, D'Silva A, Vucic S, Kiernan MC, Kasparian NA, Farrar MA. Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. Orphanet J Rare Dis 2020;15:70. [PMID: 32164772 DOI: 10.1186/s13023-020-1339-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
79 Brener A, Lebenthal Y, Shtamler A, Levy S, Stein R, Fattal-Valevski A, Sagi L. The endocrine manifestations of spinal muscular atrophy, a real-life observational study. Neuromuscul Disord 2020;30:270-6. [PMID: 32273202 DOI: 10.1016/j.nmd.2020.02.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
80 Hully M, Barnerias C, Chabalier D, Le Guen S, Germa V, Deladriere E, Vanhulle C, Cuisset JM, Chabrol B, Cances C, Vuillerot C, Espil C, Mayer M, Nougues MC, Sabouraud P, Lefranc J, Laugel V, Rivier F, Louvier UW, Durigneux J, Napuri S, Sarret C, Renouil M, Masurel A, Viallard ML, Desguerre I. Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports. Front Pediatr 2020;8:4. [PMID: 32133329 DOI: 10.3389/fped.2020.00004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
81 Ross T. Inclusive research design: Accounting for childhood disability in school transportation research. Transportation and Children's Well-Being 2020. [DOI: 10.1016/b978-0-12-814694-1.00015-4] [Reference Citation Analysis]
82 Trollmann R. Diagnostik und Therapie neurologischer Erkrankungen bei Kindern und Jugendlichen. Diagnostik und Therapie neurologischer Erkrankungen 2020. [DOI: 10.1016/b978-3-437-21882-8.00018-9] [Reference Citation Analysis]
83 Repetto GM, Rebolledo-jaramillo B. Rare Diseases: Genomics and Public Health. Applied Genomics and Public Health. Elsevier; 2020. pp. 37-51. [DOI: 10.1016/b978-0-12-813695-9.00003-0] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Elsheikh BH, Kolb SJ, Kissel JT. Spinal muscular atrophy. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease 2020. [DOI: 10.1016/b978-0-12-813866-3.00022-9] [Reference Citation Analysis]
85 Khadilkar SV, Singh RK. Nusinersen and Spinal Muscular Atrophies: Where are we in 2020? Ann Indian Acad Neurol 2020;23:743-4. [PMID: 33688120 DOI: 10.4103/aian.AIAN_887_20] [Reference Citation Analysis]
86 Ross T, Buliung R. Access work: Experiences of parking at school for families living with childhood disability. Transportation Research Part A: Policy and Practice 2019;130:289-99. [DOI: 10.1016/j.tra.2019.08.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
87 Raimer AC, Singh SS, Edula MR, Paris-davila T, Vandadi V, Spring AM, Gregory Matera A. Temperature sensitive SMA-causing point mutations lead to SMN instability, locomotor defects, and premature lethality inDrosophila.. [DOI: 10.1101/832030] [Reference Citation Analysis]
88 Ng SY, Mikhail A, Ljubicic V. Mechanisms of exercise-induced survival motor neuron expression in the skeletal muscle of spinal muscular atrophy-like mice. J Physiol 2019;597:4757-78. [PMID: 31361024 DOI: 10.1113/JP278454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
89 Alvarez K, Suarez B, Palomino MA, Hervias C, Calcagno G, Martínez-Jalilie M, Lozano-Arango A, Lillo S, Haro M, Cortés F, Pantoja S, Chahin A, Orellana P, Bevilacqua JA, Bertini E, Castiglioni C. Observations from a nationwide vigilance program in medical care for spinal muscular atrophy patients in Chile. Arq Neuropsiquiatr 2019;77:470-7. [PMID: 31365638 DOI: 10.1590/0004-282X20190073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
90 Eshraghi M, Gombar R, De Repentigny Y, Vacratsis PO, Kothary R. Pathologic Alterations in the Proteome of Synaptosomes from a Mouse Model of Spinal Muscular Atrophy. J Proteome Res 2019;18:3042-51. [PMID: 31262178 DOI: 10.1021/acs.jproteome.9b00159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
91 Kollmer J, Hilgenfeld T, Ziegler A, Saffari A, Sam G, Hayes JM, Pietsch A, Jost M, Heiland S, Bendszus M, Wick W, Weiler M. Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy. Neurology 2019;93:e653-64. [PMID: 31292223 DOI: 10.1212/WNL.0000000000007945] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
92 Taladriz-Sender A, Campbell E, Burley GA. Splice-switching small molecules: A new therapeutic approach to modulate gene expression. Methods 2019;167:134-42. [PMID: 31203161 DOI: 10.1016/j.ymeth.2019.06.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
93 Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Dabbous O. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy 2019;7:1601484. [PMID: 31105909 DOI: 10.1080/20016689.2019.1601484] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 15.0] [Reference Citation Analysis]
94 Bozorg Qomi S, Asghari A, Salmaninejad A, Mojarrad M. Spinal Muscular Atrophy and Common Therapeutic Advances. Fetal Pediatr Pathol 2019;38:226-38. [PMID: 31060440 DOI: 10.1080/15513815.2018.1520374] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Neil EE, Bisaccia EK. Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. J Pediatr Pharmacol Ther 2019;24:194-203. [PMID: 31093018 DOI: 10.5863/1551-6776-24.3.194] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 12.7] [Reference Citation Analysis]
96 Alfano LN, Miller NF, Iammarino MA, Moore Clingenpeel M, Lowes SL, Dugan ME, Kissel JT, Al Zaidy S, Tsao C, Lowes LP. ACTIVE (Ability Captured Through Interactive Video Evaluation) workspace volume video game to quantify meaningful change in spinal muscular atrophy. Dev Med Child Neurol 2020;62:303-9. [DOI: 10.1111/dmcn.14230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
97 Shorrock HK, Gillingwater TH, Groen EJN. Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy. Drugs 2018;78:293-305. [PMID: 29380287 DOI: 10.1007/s40265-018-0868-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
98 Wan HWY, Carey KA, D'Silva A, Kasparian NA, Farrar MA. "Getting ready for the adult world": how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. Orphanet J Rare Dis 2019;14:74. [PMID: 30940178 DOI: 10.1186/s13023-019-1052-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
99 Goodkey K, Aslesh T, Maruyama R, Yokota T. Nusinersen in the Treatment of Spinal Muscular Atrophy. Methods Mol Biol 2018;1828:69-76. [PMID: 30171535 DOI: 10.1007/978-1-4939-8651-4_4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
100 Human Nervous System Disorders. Examining the Causal Relationship Between Genes, Epigenetics, and Human Health 2019. [DOI: 10.4018/978-1-5225-8066-9.ch018] [Reference Citation Analysis]
101 Tiziano FD, Lomastro R, Abiusi E, Pasanisi MB, Di Pietro L, Fiori S, Baranello G, Angelini C, Sorarù G, Gaiani A, Mongini T, Vercelli L, Mercuri E, Vasco G, Pane M, Vita G, Vita G, Messina S, Petillo R, Passamano L, Politano L, Campanella A, Mantegazza R, Morandi L. Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. J Med Genet 2019;56:293-300. [DOI: 10.1136/jmedgenet-2018-105482] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
102 Saffari A, Kölker S, Hoffmann GF, Weiler M, Ziegler A. Novel challenges in spinal muscular atrophy - How to screen and whom to treat? Ann Clin Transl Neurol 2019;6:197-205. [PMID: 30656198 DOI: 10.1002/acn3.689] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
103 Glascock J, Sampson J, Haidet-Phillips A, Connolly A, Darras B, Day J, Finkel R, Howell RR, Klinger K, Kuntz N, Prior T, Shieh PB, Crawford TO, Kerr D, Jarecki J. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening. J Neuromuscul Dis 2018;5:145-58. [PMID: 29614695 DOI: 10.3233/JND-180304] [Cited by in Crossref: 96] [Cited by in F6Publishing: 105] [Article Influence: 24.0] [Reference Citation Analysis]
104 Kletzl H, Marquet A, Günther A, Tang W, Heuberger J, Groeneveld GJ, Birkhoff W, Mercuri E, Lochmüller H, Wood C, Fischer D, Gerlach I, Heinig K, Bugawan T, Dziadek S, Kinch R, Czech C, Khwaja O. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy. Neuromuscul Disord 2019;29:21-9. [PMID: 30553700 DOI: 10.1016/j.nmd.2018.10.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
105 Reed UC, Zanoteli E. Therapeutic advances in 5q-linked spinal muscular atrophy. Arq Neuropsiquiatr 2018;76:265-72. [PMID: 29742241 DOI: 10.1590/0004-282x20180011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
106 Yasemin C. Novel Complication of Nusinersen Treatment: Hyponatremia. J Clin Intensive Care Med 2018;2:020-022. [DOI: 10.29328/journal.jcicm.1001014] [Reference Citation Analysis]
107 Glaser J, Suzuki M. Skeletal Muscle Fiber Types in Neuromuscular Diseases. Muscle Cell and Tissue - Current Status of Research Field 2018. [DOI: 10.5772/intechopen.79474] [Reference Citation Analysis]
108 Sampaio H, Wilcken B, Farrar M. Screening for spinal muscular atrophy. Medical Journal of Australia 2018;209:147-148. [DOI: 10.5694/mja17.00772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
109 Bernabò P, Tebaldi T, Groen EJN, Lane FM, Perenthaler E, Mattedi F, Newbery HJ, Zhou H, Zuccotti P, Potrich V, Shorrock HK, Muntoni F, Quattrone A, Gillingwater TH, Viero G. In Vivo Translatome Profiling in Spinal Muscular Atrophy Reveals a Role for SMN Protein in Ribosome Biology. Cell Rep 2017;21:953-65. [PMID: 29069603 DOI: 10.1016/j.celrep.2017.10.010] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 16.0] [Reference Citation Analysis]
110 Farrar MA, Carey KA, Paguinto SG, Chambers G, Kasparian NA. Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives. BMJ Open 2018;8:e020907. [PMID: 29794098 DOI: 10.1136/bmjopen-2017-020907] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
111 Köelbel H, Gangfuß A, Rupprich K, Andres B, Marina AD, Schara U. Vorteil durch frühen Therapiebeginn bei proximaler spinaler Muskelatrophie. InFo Neurologie 2018;20:30-38. [DOI: 10.1007/s15005-018-2371-x] [Reference Citation Analysis]
112 Osman EY, Washington CW, Simon ME, Megiddo D, Greif H, Lorson CL. Analysis of Azithromycin Monohydrate as a Single or a Combinatorial Therapy in a Mouse Model of Severe Spinal Muscular Atrophy. J Neuromuscul Dis 2017;4:237-49. [PMID: 28598854 DOI: 10.3233/JND-170230] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
113 Kariyawasam D, Carey KA, Jones KJ, Farrar MA. New and developing therapies in spinal muscular atrophy. Paediatr Respir Rev 2018;28:3-10. [PMID: 29703692 DOI: 10.1016/j.prrv.2018.03.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
114 Farrar MA, Teoh HL, Carey KA, Cairns A, Forbes R, Herbert K, Holland S, Jones KJ, Menezes MP, Morrison M, Munro K, Villano D, Webster R, Woodcock IR, Yiu EM, Sampaio H, Ryan MM. Nusinersen for SMA: expanded access programme. J Neurol Neurosurg Psychiatry 2018;89:937-42. [PMID: 29549190 DOI: 10.1136/jnnp-2017-317412] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
115 Khalil B, Morderer D, Price PL, Liu F, Rossoll W. mRNP assembly, axonal transport, and local translation in neurodegenerative diseases. Brain Res 2018;1693:75-91. [PMID: 29462608 DOI: 10.1016/j.brainres.2018.02.018] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
116 Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14:214-224. [PMID: 29422644 DOI: 10.1038/nrneurol.2018.4] [Cited by in Crossref: 130] [Cited by in F6Publishing: 134] [Article Influence: 32.5] [Reference Citation Analysis]
117 Harel T, Lupski JR. Genomic disorders 20 years on-mechanisms for clinical manifestations. Clin Genet 2018;93:439-49. [PMID: 28950406 DOI: 10.1111/cge.13146] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 12.6] [Reference Citation Analysis]
118 Mariot V, Joubert R, Hourdé C, Féasson L, Hanna M, Muntoni F, Maisonobe T, Servais L, Bogni C, Le Panse R, Benvensite O, Stojkovic T, Machado PM, Voit T, Buj-Bello A, Dumonceaux J. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun 2017;8:1859. [PMID: 29192144 DOI: 10.1038/s41467-017-01486-4] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 15.6] [Reference Citation Analysis]
119 Konieczny P, Stepniak-Konieczna E, Sobczak K. MBNL expression in autoregulatory feedback loops. RNA Biol 2018;15:1-8. [PMID: 28949831 DOI: 10.1080/15476286.2017.1384119] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
120 Bharucha-Goebel D, Kaufmann P. Treatment Advances in Spinal Muscular Atrophy. Curr Neurol Neurosci Rep 2017;17:91. [PMID: 28983837 DOI: 10.1007/s11910-017-0798-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
121 Chiriboga CA. Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother 2017;17:955-62. [PMID: 28884620 DOI: 10.1080/14737175.2017.1364159] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 13.0] [Reference Citation Analysis]
122 Paganoni S, Nicholson K, Leigh F, Swoboda K, Chad D, Drake K, Haley K, Cudkowicz M, Berry JD. Developing multidisciplinary clinics for neuromuscular care and research. Muscle Nerve 2017;56:848-58. [PMID: 28632945 DOI: 10.1002/mus.25725] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
123 Ross LF, Clarke AJ. A Historical and Current Review of Newborn Screening for Neuromuscular Disorders From Around the World: Lessons for the United States. Pediatr Neurol 2017;77:12-22. [PMID: 29079012 DOI: 10.1016/j.pediatrneurol.2017.08.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
124 Isobe N. American Academy of Neurology 2017 Annual Meeting. Clin Exp Neuroimmunol 2017;8:273-275. [DOI: 10.1111/cen3.12402] [Reference Citation Analysis]
125 Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, Cook SF, Lochmüller H. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis 2017;12:124. [PMID: 28676062 DOI: 10.1186/s13023-017-0671-8] [Cited by in Crossref: 246] [Cited by in F6Publishing: 259] [Article Influence: 49.2] [Reference Citation Analysis]
126 Wokke JH. Another milestone in childhood spinal muscular atrophy. The Lancet Neurology 2017;16:491-2. [DOI: 10.1016/s1474-4422(17)30121-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
127 Lanfranco M, Vassallo N, Cauchi RJ. Spinal Muscular Atrophy: From Defective Chaperoning of snRNP Assembly to Neuromuscular Dysfunction. Front Mol Biosci 2017;4:41. [PMID: 28642865 DOI: 10.3389/fmolb.2017.00041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
128 Teoh HL, Carey K, Sampaio H, Mowat D, Roscioli T, Farrar M. Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy. Neural Plast 2017;2017:6509493. [PMID: 28634552 DOI: 10.1155/2017/6509493] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
129 Hoy SM. Nusinersen: First Global Approval. Drugs 2017;77:473-9. [PMID: 28229309 DOI: 10.1007/s40265-017-0711-7] [Cited by in Crossref: 123] [Cited by in F6Publishing: 126] [Article Influence: 24.6] [Reference Citation Analysis]
130 Glascock J, Lenz M, Hobby K, Jarecki J. Cure SMA and our patient community celebrate the first approved drug for SMA. Gene Ther 2017;24:498-500. [PMID: 28504658 DOI: 10.1038/gt.2017.39] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
131 Ansseau E, Vanderplanck C, Wauters A, Harper SQ, Coppée F, Belayew A. Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). Genes (Basel) 2017;8:E93. [PMID: 28273791 DOI: 10.3390/genes8030093] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
132 Verma A. Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases. Ann Indian Acad Neurol 2018;21:3-8. [PMID: 29720791 DOI: 10.4103/aian.AIAN_298_17] [Cited by in F6Publishing: 16] [Reference Citation Analysis]